TVTX Travere Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TVTX

Price (delayed)

$59.83

Market cap

$5.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$6.14B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 45

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product ...

Highlights
The quick ratio has soared by 98% YoY and by 33% from the previous quarter
Travere Therapeutics's gross profit has surged by 80% YoY and by 10% QoQ
The company's EPS has shrunk by 105% QoQ but it has surged by 78% YoY
TVTX's net income has dropped by 103% since the previous quarter but it has surged by 74% year-on-year
The debt has soared by 88% since the previous quarter and by 54% year-on-year
TVTX's equity has dropped by 75% since the previous quarter and by 25% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.retrophin.com
Peers: OPK ORGO

Key stats

What are the main financial stats of TVTX

TVTX stock price

How has the Travere Therapeutics stock price performed over time
Intraday
-0.75%
1 week
-5.75%
1 month
-8.95%
1 year
146.93%
YTD
56.58%
QTD
5.32%

Financial performance

How have Travere Therapeutics's revenue and profit performed over time
Revenue
$591.33M
Gross profit
$583.07M
Operating income
-$40.46M
Net income
-$43.46M
Gross margin
98.6%
Net margin
-7.4%
TVTX's net income has dropped by 103% since the previous quarter but it has surged by 74% year-on-year
The operating margin has soared by 87% YoY and by 36% from the previous quarter
The net margin has soared by 85% year-on-year but it has dropped by 85% since the previous quarter
Travere Therapeutics's gross profit has surged by 80% YoY and by 10% QoQ

Price vs fundamentals

How does TVTX's price correlate with its fundamentals

Growth

What is Travere Therapeutics's growth rate over time

Valuation

What is Travere Therapeutics stock price valuation
P/E
N/A
P/B
226.89
P/S
9.46
EV/EBIT
N/A
EV/EBITDA
204.67
EV/Sales
10.38
The company's EPS has shrunk by 105% QoQ but it has surged by 78% YoY
TVTX's equity has dropped by 75% since the previous quarter and by 25% year-on-year
The revenue has surged by 77% year-on-year and by 10% since the previous quarter
The stock's P/S is 47% above its last 4 quarters average of 6.5 and 21% above its 5-year quarterly average of 7.9

Efficiency

How efficient is Travere Therapeutics business performance
The company's return on sales has shrunk by 195% QoQ but it has surged by 88% YoY
The return on invested capital has dropped by 163% since the previous quarter but it has surged by 81% year-on-year
Travere Therapeutics's return on equity has shrunk by 108% QoQ but it has surged by 92% YoY
The company's return on assets has shrunk by 84% QoQ but it has surged by 77% YoY

Dividends

What is TVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TVTX.

Financial health

How did Travere Therapeutics financials performed over time
TVTX's total assets is 3.2% more than its total liabilities
The company's current ratio has surged by 103% YoY and by 29% QoQ
The quick ratio has soared by 98% YoY and by 33% from the previous quarter
Travere Therapeutics's debt to equity has soared by 106% YoY
The debt has soared by 88% since the previous quarter and by 54% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.